Clinical trialNCT05887609RecruitingPhase 2Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

SponsorUniversity of Colorado, DenverEnrollment53Fallopian Tube CancerOvary CancerPeritoneal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bradley Corr, MD
University of Colorado, Denver
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Lennar
Irvine, California, United States
Recruiting
University of Colorado Hospital
Aurora, Colorado, United States
Bradley Corr, MD
Recruiting
Northwestern Memorial Hospital
Chicago, Illinois, United States
Emma Barber, MD
Recruiting
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Stefan Gysler, MD
Recruiting
Upmc Magee-Women'S Hospital
Pittsburgh, Pennsylvania, United States
Lisa Barroilhet, MD
Recruiting
University of Wisconsin - Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Lisa Barroilhet, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mirvetuximab soravtansine →Olaparib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Oct 2023
Primary completion: 31 Jan 2029
Completion: 31 Jan 2031
Last update posted: 13 Jul 2026
Registered enrollment: 53
Registry id: NCT05887609

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.